A vaccine for COVID-19 is being developed by privately-held Medicago, with the research being partially funded by the Governments of Canada and Quebec.Current status: The vaccine, which is developed using a plant-based platform, is currently in phase I trial.Mode of Action: The vaccine is a recombinant coronavirus VLP (CoVLP). Virus-like Particles, or VLPs, mimic the native structure of viruses, allowing them to be easily recognized by the immune system.Next milestone:If the phase I trial results are positive, the company expects to launch phase II/III trials in October 2020.